Joachim Burman (Uppsala University, Sweden) explains to us the rationale for the use of autologous non-myeloablative hematopoietic stem cell transplant (autoHSCT) in patients with relapsing remitting multiple sclerosis, and shares his insight on the MIST (Multiple Sclerosis International Stem cell Transplant) study findings.
Questions
1. What is the rationale for the use of autologous non-myeloablative hematopoietic stem cell transplant (autoHSCT) in patients with relapsing remitting multiple sclerosis? (0:04)
2. Could you tell us a little about the MIST (Multiple Sclerosis International Stem cell Transplant) study and its findings? (0:40)
3. What are the risks of this treatment? (1:44)
4. Which patients are most likely to respond to autoHSCT? (2:43)
5. What were the limitations of the MIST study and what further studies are planned? (3:11)
Speaker disclosure: Joachim Burman has nothing to disclose in relation to this video interview.
Filmed at the 5th Congress of the European Academy of Neurology (EAN), Oslo, Norway, June 2019.
